EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 268 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Teacher Reads To Students One Day After Having Brain Surgery October 26, 2021 EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... February 19, 2021 Should alcohol marketing be dropped from televised sport? August 27, 2021 An Increase in Healthcare Costs Associated with the Use of Multigene... February 14, 2024 Load more HOT NEWS Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors EMA Recommends Extension of Indications for Durvalumab in the Management of... A Combination of Durvalumab-Tremelimumab with mFOLFOX6 Is Tolerable with Promising Activity... FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
